$ENTX
Entera Bio Ltd

2022 Q2 Form 10-Q Financial Statement

#000117891322003056 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $44.00K $68.00K $571.0K
YoY Change -59.63% -57.5% 159.55%
Cost Of Revenue $33.00K $54.00K $373.0K
YoY Change -66.67% -10.0% 239.09%
Gross Profit $11.00K $14.00K $198.0K
YoY Change 10.0% -86.0% 65.0%
Gross Profit Margin 25.0% 20.59% 34.68%
Selling, General & Admin $1.880M $2.171M $5.690M
YoY Change 29.66% 65.73% 358.87%
% of Gross Profit 17090.91% 15507.14% 2873.74%
Research & Development $1.394M $1.690M $6.771M
YoY Change 13.61% 45.69% 473.81%
% of Gross Profit 12672.73% 12071.43% 3419.7%
Depreciation & Amortization $16.00K $16.00K $53.00K
YoY Change -82.22% -33.75%
% of Gross Profit 145.45% 114.29% 26.77%
Operating Expenses $3.260M $3.849M $12.42M
YoY Change 26.36% 56.46% 415.15%
Operating Profit -$3.249M -$3.835M -$12.22M
YoY Change 26.42% 62.5% 433.49%
Interest Expense $60.00K $44.00K -$29.00K
YoY Change -102.47% -100.62% -126.36%
% of Operating Profit
Other Income/Expense, Net $60.00K $44.00K
YoY Change -350.0% 340.0%
Pretax Income -$3.189M -$3.791M -$12.25M
YoY Change 22.94% -59.88% 449.15%
Income Tax -$4.000K -$7.000K -$59.00K
% Of Pretax Income
Net Earnings -$3.185M -$3.784M -$12.19M
YoY Change 23.59% 64.81% 441.64%
Net Earnings / Revenue -7238.64% -5564.71% -2134.33%
Basic Earnings Per Share $0.11 $0.13
Diluted Earnings Per Share $0.11 -$131.4K -$466.3K
COMMON SHARES
Basic Shares Outstanding 28.81M shares 28.80M shares
Diluted Shares Outstanding 28.81M shares 28.80M shares

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.28M $20.11M $24.89M
YoY Change -35.83% 22.77% 189.78%
Cash & Equivalents $17.28M $20.11M $24.89M
Short-Term Investments
Other Short-Term Assets $922.0K $1.322M $254.0K
YoY Change 6.84% 27.12% -2.68%
Inventory
Prepaid Expenses
Receivables $225.0K $210.0K $183.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $18.43M $21.64M $25.33M
YoY Change -33.97% 24.16% 178.07%
LONG-TERM ASSETS
Property, Plant & Equipment $166.0K $163.0K $156.0K
YoY Change -61.31% -66.73% -18.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $326.0K $296.0K $263.0K
YoY Change
Total Long-Term Assets $662.0K $671.0K $658.0K
YoY Change -35.98% -39.0% 7.34%
TOTAL ASSETS
Total Short-Term Assets $18.43M $21.64M $25.33M
Total Long-Term Assets $662.0K $671.0K $658.0K
Total Assets $19.09M $22.31M $25.99M
YoY Change -34.04% 20.41% 167.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $109.0K $199.0K $166.0K
YoY Change -62.28% -54.77% 1.22%
Accrued Expenses $1.563M $1.975M $2.980M
YoY Change
Deferred Revenue $0.00 $0.00 $15.00K
YoY Change -90.51%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.692M $2.334M $3.161M
YoY Change -49.48% -78.02% 71.7%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities $127.0K $233.0K $261.0K
YoY Change 44.32% 191.25% 226.25%
Total Long-Term Liabilities $127.0K $233.0K $261.0K
YoY Change -53.82% -22.33% -29.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.692M $2.334M $3.161M
Total Long-Term Liabilities $127.0K $233.0K $261.0K
Total Liabilities $1.819M $2.567M $3.422M
YoY Change -49.81% -76.47% 54.7%
SHAREHOLDERS EQUITY
Retained Earnings -$89.40M -$86.20M -$82.43M
YoY Change 17.35%
Common Stock $106.6M $105.9M $105.0M
YoY Change 35.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $17.27M $19.75M $22.57M
YoY Change
Total Liabilities & Shareholders Equity $19.09M $22.31M $25.99M
YoY Change -34.04% 20.41% 167.3%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$3.185M -$3.784M -$12.19M
YoY Change 23.59% 64.81% 441.64%
Depreciation, Depletion And Amortization $16.00K $16.00K $53.00K
YoY Change -82.22% -33.75%
Cash From Operating Activities -$2.827M -$4.792M -$2.475M
YoY Change 27.46% 110.18% 78.06%
INVESTING ACTIVITIES
Capital Expenditures -$19.00K -$23.00K -$10.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$19.00K -$23.00K -$10.00K
YoY Change -75.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 13.00K 0.000 166.0K
YoY Change -99.9% -100.0% -94.39%
NET CHANGE
Cash From Operating Activities -2.827M -4.792M -2.475M
Cash From Investing Activities -19.00K -23.00K -10.00K
Cash From Financing Activities 13.00K 0.000 166.0K
Net Change In Cash -2.833M -4.815M -2.319M
YoY Change -127.23% -161.89% -251.57%
FREE CASH FLOW
Cash From Operating Activities -$2.827M -$4.792M -$2.475M
Capital Expenditures -$19.00K -$23.00K -$10.00K
Free Cash Flow -$2.808M -$4.769M -$2.465M
YoY Change 26.6% 109.17% 77.34%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0000769
CY2022Q2 entx Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
1400000 shares
CY2022Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
700000 shares
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000 usd
CY2021Q2 entx Exercise Of Warrants Value
ExerciseOfWarrantsValue
3134000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17316000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26996000 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0000769
CY2022Q2 entx Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
1400000 shares
CY2022Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
700000 shares
entx Net Proceeds From Issuance Of Common Stock
NetProceedsFromIssuanceOfCommonStock
9600000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-89400000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6326180 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7804106 shares
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6473863 shares
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7718887 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
The options vest over four years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date. The fair value of the options at the date of grant was $147.
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
147000 usd
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
55000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6326180 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7804106 shares
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6473863 shares
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7718887 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
The options vest over four years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date. The fair value of the options at the date of grant was $147.
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
147000 usd
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
55000 shares
CY2022Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
20000 usd
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
134000 usd
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
42000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-42000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd

Files In Submission

Name View Source Status
0001178913-22-003056-index-headers.html Edgar Link pending
0001178913-22-003056-index.html Edgar Link pending
0001178913-22-003056.txt Edgar Link pending
0001178913-22-003056-xbrl.zip Edgar Link pending
entx-20220630.xsd Edgar Link pending
exhibit_31-1.htm Edgar Link pending
exhibit_31-2.htm Edgar Link pending
exhibit_32-1.htm Edgar Link pending
exhibit_32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
entx-20220630_def.xml Edgar Link unprocessable
entx-20220630_lab.xml Edgar Link unprocessable
entx-20220630_pre.xml Edgar Link unprocessable
entx-20220630_cal.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zk2228270.htm Edgar Link pending
zk2228270_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable